Dashboard
1
With ROE of 20.03%, it has a very attractive valuation with a 2.07 Price to Book Value
- Over the past year, while the stock has generated a return of 19.39%, its profits have risen by 21.2% ; the PEG ratio of the company is 0.5
- At the current price, the company has a high dividend yield of 4.9
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,161 Million (Small Cap)
10.00
NA
4.90%
-0.10
20.03%
2.07
Revenue and Profits:
Net Sales:
409 Million
(Quarterly Results - Mar 2026)
Net Profit:
75 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.09%
0%
22.09%
6 Months
11.59%
0%
11.59%
1 Year
35.76%
0%
35.76%
2 Years
34.39%
0%
34.39%
3 Years
29.58%
0%
29.58%
4 Years
-16.66%
0%
-16.66%
5 Years
3.72%
0%
3.72%
Jiang Xi Sanxin Medtec Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.73%
EBIT Growth (5y)
13.98%
EBIT to Interest (avg)
71.65
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
0.89
Tax Ratio
10.16%
Dividend Payout Ratio
58.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.45%
ROE (avg)
18.36%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
2.07
EV to EBIT
9.75
EV to EBITDA
7.49
EV to Capital Employed
2.18
EV to Sales
1.78
PEG Ratio
0.49
Dividend Yield
4.90%
ROCE (Latest)
22.39%
ROE (Latest)
20.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
408.90
360.60
13.39%
Operating Profit (PBDIT) excl Other Income
81.20
90.50
-10.28%
Interest
0.70
0.40
75.00%
Exceptional Items
1.40
1.10
27.27%
Consolidate Net Profit
75.40
59.40
26.94%
Operating Profit Margin (Excl OI)
198.60%
169.30%
2.93%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 13.39% vs 9.74% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 26.94% vs 2.95% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,632.70
1,493.90
9.29%
Operating Profit (PBDIT) excl Other Income
417.80
356.00
17.36%
Interest
2.90
4.00
-27.50%
Exceptional Items
0.00
-12.10
100.00%
Consolidate Net Profit
290.30
247.70
17.20%
Operating Profit Margin (Excl OI)
180.80%
177.30%
0.35%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 9.29% vs 15.37% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 17.20% vs 10.98% in Dec 2024
About Jiang Xi Sanxin Medtec Co., Ltd. 
Jiang Xi Sanxin Medtec Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






